The move gives the French drug giant access to Kiadis’ natural killer cell technology platform

The oral, once-daily therapy is designed to prevent attacks and reduce burden of therapy

Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive […]